In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment - PubMed (original) (raw)
Review
. 2010 Feb;54(2):195-207.
doi: 10.1002/mnfr.200900211.
Affiliations
- PMID: 19943261
- DOI: 10.1002/mnfr.200900211
Review
In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment
Ivonne M C M Rietjens et al. Mol Nutr Food Res. 2010 Feb.
Abstract
In chemical safety assessment, information on adverse effects after chronic exposure to low levels of hazardous compounds is essential for estimating human risks. Results from in vitro studies are often not directly applicable to the in vivo situation, and in vivo animal studies often have to be performed at unrealistic high levels of exposure. Physiologically based biokinetic (PBBK) modeling can be used as a platform for integrating in vitro metabolic data to predict dose- and species-dependent in vivo effects on biokinetics, and can provide a method to obtain a better mechanistic basis for extrapolations of data obtained in experimental animal studies to the human situation. Recently, we have developed PBBK models for the bioactivation of the alkenylbenzene estragole to its DNA binding ultimate carcinogenic metabolite 1'-sulfooxyestragole in both rat and human, as well as rat and human PBBK models for the bioactivation of coumarin to its hepatotoxic o-hydroxyphenylacetaldehyde metabolite. This article presents an overview of the results obtained so far with these in silico methods for PBBK modeling, focusing on the possible implications for risk assessment, and some additional considerations and future perspectives.
Similar articles
- A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat.
Punt A, Freidig AP, Delatour T, Scholz G, Boersma MG, Schilter B, van Bladeren PJ, Rietjens IM. Punt A, et al. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):248-59. doi: 10.1016/j.taap.2008.04.011. Epub 2008 Apr 27. Toxicol Appl Pharmacol. 2008. PMID: 18539307 - A physiologically based biodynamic (PBBD) model for estragole DNA binding in rat liver based on in vitro kinetic data and estragole DNA adduct formation in primary hepatocytes.
Paini A, Punt A, Viton F, Scholz G, Delatour T, Marin-Kuan M, Schilter B, van Bladeren PJ, Rietjens IM. Paini A, et al. Toxicol Appl Pharmacol. 2010 May 15;245(1):57-66. doi: 10.1016/j.taap.2010.01.016. Epub 2010 Feb 6. Toxicol Appl Pharmacol. 2010. PMID: 20144636 - Identification of nevadensin as an important herb-based constituent inhibiting estragole bioactivation and physiology-based biokinetic modeling of its possible in vivo effect.
Alhusainy W, Paini A, Punt A, Louisse J, Spenkelink A, Vervoort J, Delatour T, Scholz G, Schilter B, Adams T, van Bladeren PJ, Rietjens IM. Alhusainy W, et al. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):179-90. doi: 10.1016/j.taap.2010.02.017. Epub 2010 Mar 11. Toxicol Appl Pharmacol. 2010. PMID: 20226806 - Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials. EFSA GMO Panel Working Group on Animal Feeding Trials. Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review. - Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk.
Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM. Rietjens IM, et al. Mutat Res. 2005 Jul 1;574(1-2):124-38. doi: 10.1016/j.mrfmmm.2005.01.028. Epub 2005 Mar 31. Mutat Res. 2005. PMID: 15914212 Review.
Cited by
- Combined Risk Assessment of Food-derived Coumarin with in Silico Approaches.
Yamada T, Katsutani N, Maruyama T, Kawamura T, Yamazaki H, Murayama N, Tong W, Yamazoe Y, Hirose A. Yamada T, et al. Food Saf (Tokyo). 2022 Sep 23;10(3):73-82. doi: 10.14252/foodsafetyfscj.D-21-00015. eCollection 2022 Sep. Food Saf (Tokyo). 2022. PMID: 36237397 Free PMC article. - Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs.
Yuan Y, He Q, Zhang S, Li M, Tang Z, Zhu X, Jiao Z, Cai W, Xiang X. Yuan Y, et al. Front Pharmacol. 2022 May 12;13:895556. doi: 10.3389/fphar.2022.895556. eCollection 2022. Front Pharmacol. 2022. PMID: 35645843 Free PMC article. - Mode of action-based risk assessment of genotoxic carcinogens.
Hartwig A, Arand M, Epe B, Guth S, Jahnke G, Lampen A, Martus HJ, Monien B, Rietjens IMCM, Schmitz-Spanke S, Schriever-Schwemmer G, Steinberg P, Eisenbrand G. Hartwig A, et al. Arch Toxicol. 2020 Jun;94(6):1787-1877. doi: 10.1007/s00204-020-02733-2. Epub 2020 Jun 15. Arch Toxicol. 2020. PMID: 32542409 Free PMC article. Review. - The safety evaluation of food flavouring substances: the role of metabolic studies.
Smith RL, Cohen SM, Fukushima S, Gooderham NJ, Hecht SS, Guengerich FP, Rietjens IMCM, Bastaki M, Harman CL, McGowen MM, Taylor SV. Smith RL, et al. Toxicol Res (Camb). 2018 Mar 28;7(4):618-646. doi: 10.1039/c7tx00254h. eCollection 2018 Jul 1. Toxicol Res (Camb). 2018. PMID: 30090611 Free PMC article. Review. - Can estragole in fennel seed decoctions really be considered a danger for human health? A fennel safety update.
Gori L, Gallo E, Mascherini V, Mugelli A, Vannacci A, Firenzuoli F. Gori L, et al. Evid Based Complement Alternat Med. 2012;2012:860542. doi: 10.1155/2012/860542. Epub 2012 Jul 29. Evid Based Complement Alternat Med. 2012. PMID: 22899959 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources